http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2780791-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b180e9f4d9a057dbdea36d6fdc73a60 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 1998-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75f303b8c3b0b8f7ee20f1ef4a7c7665 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6497a636a73faee73f23c19e952da6bc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edca8de8d2d68cc341898384cc4a4bed |
| publicationDate | 2000-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | FR-2780791-A1 |
| titleOfInvention | METHOD OF SCREENING OR DIAGNOSIS OF ADENOCARCINOMA OR BENIGN PROSTATE PATHOLOGY AND PROCESS FOR IMPLEMENTATION |
| abstract | The present invention relates to a method for diagnosing prostate adenocarcinoma in a male human patient, without performing a prostate biopsy, which uses prostate specific antigen (PSA) protein present in blood, serum, urine or seminal fluid of the patient. It consists of: a) measuring the level of total free PSA, that is to say cleaved or uncleaved, b) measuring the level of all or part of the cleaved free PSA, c) calculating the proportion of free PSA cleaved by report to total free PSA, and d) diagnose that the patient is:. has an adenocarcinoma of the prostate, when this ratio is less than or equal to a reference value, or. has a benign prostate disease, such as benign prostatic hypertrophy, when this ratio is greater than the reference value. It is also possible to calculate the proportion of free uncleaved PSA relative to total free PSA or the proportion of free PSA cleaved relative to uncleaved free PSA or total PSA or complexed PSA. The invention is applied to the diagnosis of adenocarcinoma or benign prostatic hypertrophy. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0196876-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7517653-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0177180-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102520161-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2810114-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004013418-A1 |
| priorityDate | 1998-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.